Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone858-202-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.33 billion
Profitability
Miscellaneous
Employees6,200
OptionableOptionable
Illumina (NASDAQ:ILMN) Frequently Asked Questions
What is Illumina's stock symbol?
Illumina trades on the NASDAQ under the ticker symbol "ILMN."
How were Illumina's earnings last quarter?
Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Tuesday, January, 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.36 by $0.04. The life sciences company earned $867 million during the quarter, compared to analyst estimates of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. The company's revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the business posted $1.44 earnings per share. View Illumina's Earnings History.
When is Illumina's next earnings date?
What guidance has Illumina issued on next quarter's earnings?
Illumina issued an update on its FY19 earnings guidance on Tuesday, January, 29th. The company provided earnings per share (EPS) guidance of $6.50-6.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.44. The company issued revenue guidance of +13-14% to $3.76-3.80 billion, compared to the consensus revenue estimate of $3.79 billion.Illumina also updated its FY 2019 guidance to $6.50-6.60 EPS.
What price target have analysts set for ILMN?
14 brokerages have issued 12 month target prices for Illumina's stock. Their forecasts range from $271.00 to $400.00. On average, they expect Illumina's share price to reach $346.3485 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price. View Analyst Price Targets for Illumina.
What is the consensus analysts' recommendation for Illumina?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina.
Has Illumina been receiving favorable news coverage?
Media coverage about ILMN stock has trended somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Illumina earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the life sciences company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
Who are some of Illumina's key competitors?
Some companies that are related to Illumina include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO).
Who are Illumina's key executives?
Illumina's management team includes the folowing people:
- Mr. Jay T. Flatley, Exec. Chairman (Age 66)
- Mr. Francis A. deSouza, CEO, Pres & Director (Age 47)
- Mr. Sam A. Samad, CFO & Sr. VP (Age 49)
- Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)
- Mr. Mark Van Oene, Sr. VP & Chief Commercial Officer (Age 45)
Who are Illumina's major shareholders?
Illumina's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (10.94%), Oregon Public Employees Retirement Fund (7.19%), Jennison Associates LLC (3.73%), Geode Capital Management LLC (1.26%), Northern Trust Corp (1.12%) and Canada Pension Plan Investment Board (0.76%). Company insiders that own Illumina stock include A Blaine Bowman, Charles Dadswell, Daniel Bradbury, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Institutional Ownership Trends for Illumina.
Which major investors are selling Illumina stock?
ILMN stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank, Highbridge Capital Management LLC, Polar Capital LLP, Frontier Capital Management Co. LLC, Lord Abbett & CO. LLC, 1832 Asset Management L.P., State Treasurer State of Michigan and Prudential Financial Inc.. Company insiders that have sold Illumina company stock in the last year include A Blaine Bowman, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Insider Buying and Selling for Illumina.
Which major investors are buying Illumina stock?
ILMN stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Jennison Associates LLC, Massachusetts Financial Services Co. MA, Geode Capital Management LLC, Brown Advisory Inc., Bellevue Group AG, Canada Pension Plan Investment Board and Global Thematic Partners LLC. View Insider Buying and Selling for Illumina.
How do I buy shares of Illumina?
Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Illumina's stock price today?
One share of ILMN stock can currently be purchased for approximately $299.82.
How big of a company is Illumina?
Illumina has a market capitalization of $44.07 billion and generates $3.33 billion in revenue each year. The life sciences company earns $826 million in net income (profit) each year or $5.72 on an earnings per share basis. Illumina employs 6,200 workers across the globe.
What is Illumina's official website?
How can I contact Illumina?
Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]
MarketBeat Community Rating for Illumina (NASDAQ ILMN)
MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
